Bullet point summary:
What is already known:
The mitochondrial targeting agent, elamipretide, consistently improves pathologic symptoms in subjects with mitochondrial disease.
Elamipretide is safe and well-tolerated; injection site reactions are the most commonly reported adverse event.
What this study adds: